Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma 5Neoplasms 2Multiple Myeloma 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 172fludarabine phosphate 132Tacrolimus 100Mycophenolic Acid 92fludarabine 90Busulfan 88Whole-Body Irradiation 83Peripheral Blood Stem Cell Transplantation 77Antilymphocyte Serum 71Melphalan 69Filgrastim 63Cyclosporine 62Methotrexate 54Radiotherapy 40Thiotepa 39Cord Blood Stem Cell Transplantation 35Granulocyte Colony-Stimulating Factor 34Stem Cell Transplantation 32thymoglobulin 29Sirolimus 27Methylprednisolone 26Rituximab 24Cytarabine 23Clofarabine 23Etoposide 22Alemtuzumab 20Azacitidine 17Specimen Handling 14Cyclosporins 13sargramostim 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × ridaforolimus × Lymphoid × Clear all
NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
57 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡